HK1147695A1 - Pharmaceutical solid state forms - Google Patents

Pharmaceutical solid state forms

Info

Publication number
HK1147695A1
HK1147695A1 HK11101901.3A HK11101901A HK1147695A1 HK 1147695 A1 HK1147695 A1 HK 1147695A1 HK 11101901 A HK11101901 A HK 11101901A HK 1147695 A1 HK1147695 A1 HK 1147695A1
Authority
HK
Hong Kong
Prior art keywords
solid state
3alpha
5alpha
17alpha
17beta
Prior art date
Application number
HK11101901.3A
Other languages
English (en)
Inventor
Steven K White
Dwight Stickney
Erin Olson
Keith R Lorimer
Brenton S Wolfe
Original Assignee
Harbor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Therapeutics Inc filed Critical Harbor Therapeutics Inc
Publication of HK1147695A1 publication Critical patent/HK1147695A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HK11101901.3A 2008-02-05 2011-02-25 Pharmaceutical solid state forms HK1147695A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US9369408P 2008-09-02 2008-09-02
PCT/US2009/033280 WO2009100258A1 (en) 2008-02-05 2009-02-05 Pharmaceutical solid state forms

Publications (1)

Publication Number Publication Date
HK1147695A1 true HK1147695A1 (en) 2011-08-19

Family

ID=40952461

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11101901.3A HK1147695A1 (en) 2008-02-05 2011-02-25 Pharmaceutical solid state forms

Country Status (11)

Country Link
US (4) US8518922B2 (de)
EP (1) EP2249838A4 (de)
JP (1) JP2011511011A (de)
KR (1) KR20100113602A (de)
CN (2) CN101939009B (de)
AU (1) AU2009212314C1 (de)
CA (1) CA2712005C (de)
EA (1) EA018974B9 (de)
HK (1) HK1147695A1 (de)
IL (1) IL207378A0 (de)
WO (1) WO2009100258A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
PT2273994E (pt) * 2008-04-03 2016-03-15 Neurmedix Inc Formas de estado sólido de um produto farmacêutico
EP2506855A4 (de) * 2009-11-30 2014-07-30 Harbor Biosciences Inc Antikarzinomverbindungen und screeningverfahren
WO2011088226A2 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings Detection of gastrointestinal disorders
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
AU2011343599A1 (en) * 2010-12-17 2013-05-09 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
MX2016006118A (es) * 2013-11-12 2016-07-21 Vertex Pharma Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
JP2018528944A (ja) 2015-09-25 2018-10-04 コンテクスト バイオファーマ インコーポレイテッド オナプリストン中間体の製造方法
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
IL269667B2 (en) * 2017-03-30 2024-09-01 Merck Patent Gmbh Solid forms of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol, their preparation and medicinal preparations containing them
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
EP4369356A3 (de) 2018-11-30 2024-07-24 Caris MPI, Inc. Molekulare profilierung der nächsten generation
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
JP2023504270A (ja) 2019-12-02 2023-02-02 カリス エムピーアイ インコーポレイテッド 汎がんのプラチナ反応予測子

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
AU4841193A (en) 1992-08-28 1994-03-29 Lunar Corporation 1alpha,24(S)-dihydroxy vitamin D2, its formation and use
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
BRPI9708389B8 (pt) 1996-03-29 2015-12-08 Duphar Int Res compostos de piperazina e piperidina, composições farmacêuticas.
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
EP2322182A1 (de) 1999-09-30 2011-05-18 Harbor BioSciences, Inc. Androstenolderivate als Androgenrezeptormodulator
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
HU230400B1 (hu) 2000-12-14 2016-04-28 Ortho-Mcneil Pharmaceutical, Inc. Szteroid hormonkészítmények és előállításukra szolgáló eljárások
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TW200730505A (en) * 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
CN103211821A (zh) * 2006-04-22 2013-07-24 霍利斯—伊登医药公司 药物和用途
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Also Published As

Publication number Publication date
KR20100113602A (ko) 2010-10-21
US9314471B2 (en) 2016-04-19
US20130345184A1 (en) 2013-12-26
EP2249838A4 (de) 2012-05-02
CA2712005C (en) 2014-04-15
EA018974B1 (ru) 2013-12-30
EA201070713A1 (ru) 2011-08-30
US20090291932A1 (en) 2009-11-26
AU2009212314B2 (en) 2013-11-21
JP2011511011A (ja) 2011-04-07
US20130345455A1 (en) 2013-12-26
EP2249838A1 (de) 2010-11-17
EA018974B9 (ru) 2014-04-30
AU2009212314C1 (en) 2014-05-08
CN101939009A (zh) 2011-01-05
CN101939009B (zh) 2013-07-17
AU2009212314A1 (en) 2009-08-13
CA2712005A1 (en) 2009-08-13
US20130338125A1 (en) 2013-12-19
CN103467554A (zh) 2013-12-25
US8518922B2 (en) 2013-08-27
WO2009100258A1 (en) 2009-08-13
IL207378A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
HK1147695A1 (en) Pharmaceutical solid state forms
PH12019501792A1 (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
HRP20150437T1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
TN2010000040A1 (en) 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
TN2012000171A1 (en) Synthetic methods for spiro-oxindole compounds
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
EP2523678A4 (de) Wnt-antagonisten sowie behandlungs- und screening-verfahren dafür
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
SG10201811480WA (en) Therapeutic compounds and compositions
EP2582676A4 (de) Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren
WO2014194245A3 (en) Cdk8 inhibitors and uses thereof
MY160075A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
EP2239257A4 (de) Neues chinazolin-2,4-dion-derivat und medizinische zusammensetzungen zur prophylaxe und behandlung von kranialer nervenkrankheit damit
EP2073635A4 (de) Makrozyklische spiropiperidin-beta-sekretase-hemmer zur behandlung von morbus alzheimer
IL195969A0 (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
UA97374C2 (ru) Производные азаиндола с комбинацией частичного агонизма к никотиновому ацетилхолиновому рецептору и ингибирование обратного захвата допамина
MX2010013608A (es) Pirroles sustituidos y metodos de uso.
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170205